Please login to the form below

Not currently logged in
Email:
Password:

Caelyx

This page shows the latest Caelyx news and features for those working in and with pharma, biotech and healthcare.

Pfizer closes on EU approval of lung cancer drug Vizimpro

Pfizer closes on EU approval of lung cancer drug Vizimpro

been developed as an alternative to Janssen-Cilag’s Caelyx.

Latest news

  • NICE recommends two drugs for ovarian cancer but rejects three NICE recommends two drugs for ovarian cancer but rejects three

    Paclitaxel and Caelyx given preliminary nod. NICE has recommended paclitaxel and Jansen-Cilag's Caleyx for the treatment of ovarian cancer in draft guidance. ... Both paclitaxel and Caelyx (pegylated liposomal doxorubicin hydrochloride) are recommended

  • Price cut keeps Kadcyla on CDF Price cut keeps Kadcyla on CDF

    The others are Pfizer's leukaemia treatment Bosulif (bosutinib), Takeda's Adcetris (brentuximab vedotin) for Hodgkin's lymphoma and Janssen's sarcoma therapy Caelyx.

  • Pharma condemns Cancer Drugs Fund cuts Pharma condemns Cancer Drugs Fund cuts

    Sarcoma. Janssen. Caelyx (doxorubicin hydrochloride). Sarcoma. Velcade (bortezomib). Lymphoma (2 indications), multiple myeloma.

  • NICE rejection of three ovarian cancer drugs stands

    Paclitaxel and Janssen's Caelyx backed. However, NICE was happy to continue to recommend two other medicines for ovarian cancer, namely: the generic chemotherapy regimen paclitaxel and Janssen's Caelyx (pegylated

  • NHS names drugs to be re-evaluated for Cancer Drugs Fund NHS names drugs to be re-evaluated for Cancer Drugs Fund

    Breast cancer. Votrient (pazopanib). Sarcoma. Janssen. Caelyx (doxorubicin hydrochloride). Sarcoma. Velcade (bortezomib)   . Lymphoma (2 indications ), myeloma (2 indications). Lilly. Alimta (pemetrexed). Lung cancer (2 indications).

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics